One hundred and one depressed inpatients were treated by the authors with a second-generation antidepressive original molecule: Toloxatone, a specific and reversible MAO A inhibitor. Upon admission, all 101 patients with depressive illness did not score higher than 20 on Hamilton's Scale, and did not score lower than 4 on Fischer, Fernández Labriola and Rodríguez Casanova's Endogeneity Test. Biological profiles (Phenyl-ethylamine, NA, and MHPG) were available on 57 subjects. At the beginning of the experiment: (a) No subject was taking antidepressives, (b) Patients' age averaged 46; (c) The 6-week experiment was a double-blind vs. placebo type. Daily toloxatone dose was standardized in a 400 mg intake. Significant modifications were detected in 51 subjects. Among the 59 subjects that were administered active substance, 37 achieved either "excellent" or "good" outcomes. Biological markers pointed out a profile of patients with a better response to Toloxatone: Namely, patients with a lower noradrenergic activity. Anxiety-free depression as well as inhibited depressions are a psychiatrist's choice for administering Toloxatone.